Brain cancer vaccine - Northwest Biotherapeutics

Drug Profile

Brain cancer vaccine - Northwest Biotherapeutics

Alternative Names: DCVax-Brain; DCVax-Brain personalised immune therapy - Northwest Biotherapeutics; DCVax-L; DCVax-L (Glioblastoma)

Latest Information Update: 18 Aug 2015

Price : $50

At a glance

  • Originator Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma

Most Recent Events

  • 18 Aug 2015 Phase-III development in Glioblastoma (Newly diagnosed) is ongoing in USA, Canada, United Kingdom and Germany (NCT00045968)
  • 27 Mar 2015 Efficacy and adverse events data from a expanded access protocol trial in Glioblastoma released by Northwest Biotherapeutics
  • 01 Feb 2015 Phase-III clinical trials in Glioblastoma in Canada (Intradermal) (NCT00045968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top